ReviewCurrent hematologic malignancy reports2009
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
Review in Current hematologic malignancy reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 25 citations in OpenAlex.
- Acetylshikonin suppresses diffuse large B-Cell Lymphoma cell growth by targeting the T-lymphokine-activated killer cell-originated protein kinase signalling pathway.Bioengineered · 2022Article
- MicroRNA profiles in B-cell non-Hodgkin lymphoma.EJIFCC · 2019Review
- High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.Annals of hematology · 2017Article
- miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.Protein & cell · 2016Article
- MicroRNAs in diffuse large B-cell lymphoma.Oncology letters · 2016Article
- Challenges and opportunities of microRNAs in lymphomas.Molecules (Basel, Switzerland) · 2014Review
- FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma.Journal of hematopathology · 2013Article
- Micro-RNA Expression and Function in Lymphomas.Advances in hematology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in Western countries and represents a heterogeneous group of diseases. Historically, the disease has been stratified based solely on clinical prognostic factors, such as those that make up the International Prognostic Index (IPI). In the past decade, many advances have been made in understanding the biology of DLBCL, including clinical aspects, gene expression profiling, and microRNA. These evaluations have revealed several distinct subtypes with differing responses to therapy and different long-term outcomes, but the standard initial therapy for DLBCL continues to use regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regardless of the disease subtype. Despite improvements in the diagnosis and treatment of this condition, nearly one third of patients die of their disease. This article reviews the history of DLBCL, prognostic factors, therapy, and possible future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.